Undisclosed panFLT3 inhibitor / Kurome - LARVOL DELTA

Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers (Businesswire) - “Kurome Therapeutics…announced the closing of a $15 million Series A financing…‘This financing allows us to expand our R&D program to substantially de-risk compound selection as we identify our first development candidate in advance of IND filing…The funding will support the pre-clinical advancement of dual IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of both targeted therapy and chemotherapy drugs via adaptive resistance mechanisms, having co-opted IRAK1/4-mediated immune signaling pathways to survive.”

Financing • Oncology • Solid Tumor